INDV - INDIVIOR PLC

32.97
-0.570   -1.729%

Share volume: 1,112,565
Last Updated: 01-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$33.54
-0.57
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
67%
Profitability 71%
Dept financing 43%
Liquidity 53%
Performance 72%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
-9.92%
6 Months
33.27%
1 Year
239.90%
2 Year
284.27%
Key data
Stock price
$32.97
P/E Ratio 
21.33
DAY RANGE
$32.82 - $33.84
EPS 
$1.68
52 WEEK RANGE
$8.64 - $38.00
52 WEEK CHANGE
$246.32
MARKET CAP 
4.480 B
YIELD 
N/A
SHARES OUTSTANDING 
125.065 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Mark Crossley
Region: US
Website: www.indivior.com/en
Employees: 0
IPO year: 2014
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Recent news